BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2621 related articles for article (PubMed ID: 16827106)

  • 21. Efficacy and mechanism of action of Proellex, an antiprogestin in aromatase overexpressing and Letrozole resistant T47D breast cancer cells.
    Gupta A; Mehta R; Alimirah F; Peng X; Murillo G; Wiehle R; Mehta RG
    J Steroid Biochem Mol Biol; 2013 Jan; 133():30-42. PubMed ID: 22939887
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Cytotoxicity of tamoxifen and its principal metabolites in human breast cancer cell lines].
    Bachmann-Moisson N; Barberi-Heyob M; Merlin JL; Ledrich ML; Batt AM; Guillemin F
    Bull Cancer; 1996 Oct; 83(10):808-15. PubMed ID: 8952630
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.
    Cui X; Schiff R; Arpino G; Osborne CK; Lee AV
    J Clin Oncol; 2005 Oct; 23(30):7721-35. PubMed ID: 16234531
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy.
    Osipo C; Gajdos C; Cheng D; Jordan VC
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):249-56. PubMed ID: 15860267
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Investigation of elemene-induced reversal of tamoxifen resistance in MCF-7 cells through oestrogen receptor α (ERα) re-expression.
    Zhang B; Zhang X; Tang B; Zheng P; Zhang Y
    Breast Cancer Res Treat; 2012 Nov; 136(2):399-406. PubMed ID: 23053650
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of tamoxifen on transcriptional level of transforming growth factor beta (TGF-beta) isoforms 1 and 2 in tumor tissue during primary treatment of patients with breast cancer.
    Brandt S; Kopp A; Grage B; Knabbe C
    Anticancer Res; 2003; 23(1A):223-9. PubMed ID: 12680217
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term treatment with tamoxifen facilitates translocation of estrogen receptor alpha out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells.
    Fan P; Wang J; Santen RJ; Yue W
    Cancer Res; 2007 Feb; 67(3):1352-60. PubMed ID: 17283173
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The relationship between the insulin-like growth factor-1 system and the oestrogen metabolising enzymes in breast cancer tissue and its adjacent non-cancerous tissue.
    Chong YM; Colston K; Jiang WG; Sharma AK; Mokbel K
    Breast Cancer Res Treat; 2006 Oct; 99(3):275-88. PubMed ID: 16752221
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estrogen receptor-α36 is involved in development of acquired tamoxifen resistance via regulating the growth status switch in breast cancer cells.
    Li G; Zhang J; Jin K; He K; Zheng Y; Xu X; Wang H; Wang H; Li Z; Yu X; Teng X; Cao J; Teng L
    Mol Oncol; 2013 Jun; 7(3):611-24. PubMed ID: 23499324
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of mitochondria in tamoxifen-induced rapid death of MCF-7 breast cancer cells.
    Kallio A; Zheng A; Dahllund J; Heiskanen KM; Härkönen P
    Apoptosis; 2005 Dec; 10(6):1395-410. PubMed ID: 16215679
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
    J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tamoxifen-resistant fibroblast growth factor-transfected MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI 182,780 and two aromatase inhibitors.
    McLeskey SW; Zhang L; El-Ashry D; Trock BJ; Lopez CA; Kharbanda S; Tobias CA; Lorant LA; Hannum RS; Dickson RB; Kern FG
    Clin Cancer Res; 1998 Mar; 4(3):697-711. PubMed ID: 9533540
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth.
    Britton DJ; Hutcheson IR; Knowlden JM; Barrow D; Giles M; McClelland RA; Gee JM; Nicholson RI
    Breast Cancer Res Treat; 2006 Mar; 96(2):131-46. PubMed ID: 16261397
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Involvement of epidermal growth factor receptor signaling pathway in tamoxifen resistance of MCF-7 cells].
    Zhen LL; Zhu X; Zheng W; Wang XY; Wu ZY
    Ai Zheng; 2006 Jul; 25(7):839-43. PubMed ID: 16831274
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phosphorylation of estrogen receptor alpha serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer.
    Yamashita H; Nishio M; Kobayashi S; Ando Y; Sugiura H; Zhang Z; Hamaguchi M; Mita K; Fujii Y; Iwase H
    Breast Cancer Res; 2005; 7(5):R753-64. PubMed ID: 16168121
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
    Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
    FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival.
    Menendez JA; Oza BP; Colomer R; Lupu R
    Int J Oncol; 2005 Jun; 26(6):1507-15. PubMed ID: 15870863
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells.
    Jordan NJ; Gee JM; Barrow D; Wakeling AE; Nicholson RI
    Breast Cancer Res Treat; 2004 Sep; 87(2):167-80. PubMed ID: 15377841
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vivo and in vitro demonstration of herb-drug interference in human breast cancer cells treated with tamoxifen and trastuzumab.
    Chen JL; Wang JY; Tsai YF; Lin YH; Tseng LM; Chang WC; King KL; Chen WS; Chiu JH; Shyr YM
    Menopause; 2013 Jun; 20(6):646-54. PubMed ID: 23340260
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reversal of ER-β silencing by chromatin modifying agents overrides acquired tamoxifen resistance.
    Pitta CA; Papageorgis P; Charalambous C; Constantinou AI
    Cancer Lett; 2013 Sep; 337(2):167-76. PubMed ID: 23752064
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 132.